Global In Vitro Diagnostics Partnering 2012-2018: Deal Trends, Players & Financials

Dublin, March 09, 2018 -- The "Global In Vitro Diagnostics Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.

The Global In Vitro Diagnostics Partnering 2012-2018 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.

The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 450 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Key benefits

• In-depth understanding of In Vitro Diagnostics deal trends since 2012
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of In Vitro Diagnostics agreements with numerous real life case studies
• Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
• Identify most active In Vitro Diagnostics dealmakers since 2012
• Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in In Vitro Diagnostics dealmaking

2.1. Introduction
2.2. In Vitro Diagnostics partnering over the years
2.3. Most active In Vitro Diagnostics dealmakers
2.4. In Vitro Diagnostics partnering by deal type
2.5. In Vitro Diagnostics partnering by therapy area
2.6. Deal terms for In Vitro Diagnostics partnering

Chapter 3 - Leading In Vitro Diagnostics deals

3.1. Introduction
3.2. Top In Vitro Diagnostics deals by value

Chapter 4 - Most active In Vitro Diagnostics dealmakers

4.1. Introduction
4.2. Most active In Vitro Diagnostics dealmakers
4.3. Most active In Vitro Diagnostics partnering company profiles

Chapter 5 - In Vitro Diagnostics contracts dealmaking directory

5.1. Introduction
5.2. In Vitro Diagnostics contracts dealmaking directory

Chapter 6 - In Vitro Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

For more information about this report visit https://www.researchandmarkets.com/research/3bqlgp/global_in_vitro?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: In Vitro Diagnostics